Sales: $3.0 billion
Major Products: Christopher Gent, chairman; Andrew Witty, chief executive officer; Simon Dingemans, chief financial officer; Emma Walmsley, president, consumer healthcare worldwide; David Redfern, chief strategy officer.
Major Products: Oral care—AquaFresh, Biotene, Dr. Best, Macleans, Odol and Sensodyne. Denture care—Polident, Poligrip and Corega.
Comments: GSK’s story in 2013 is nearly identical to what it reported in 2012. Oral care sale rose 6% last year driven by strong consumer demand for Sensodyne toothpaste for Sensitivity and Acid Erosion, which was up 15%, and sales of denture care brands, which increased 9%. However, sales of Aquafresh fell 12%.
Back in 2012, oral care sales were up 5%, driven by a double-digit gain for Sensodyne Sensitivity and Acid Erosion. Aquafresh sales fell back in 2012, too. But the drop was a more modest 2%.
For the first quarter of 2014, oral care sales increased 5% to $756 million. Sales of Sensodyne increased 13% and denture care sales rose 5% to more than offset a 14% decline in sales of Aquafresh, which the company blamed on now-resolved supply issues.